

<http://www.oblible.com>

424B2 1 d747416d424b2.htm PROSPECTUS SUPPLEMENT NO. 2944 DATED JUNE 23, 2014

[Table of Contents](#)

Regi



## The Goldman Sachs Group, Inc.

\$2,000,000

Callable Quarterly CMS Spread-Linked Notes due 2029

The notes will mature on the stated maturity date (June 26, 2029).

We may redeem your notes at 100% of their face amount plus any accrued and unpaid interest on any quarterly interest payment date on or after December 26, 2014.

On the stated maturity date, we will pay you an amount in cash equal to the face amount of your notes *plus* accrued and unpaid interest. We will pay interest quarterly, beginning September 26, 2014. For each of the first four interest periods, interest will be paid at a rate of 5.00% per annum. For each interest period thereafter, the amount of interest you will be paid each quarter will be based on the *product* of 5.00 *times* the CMS spread (the difference between the 30-year CMS rate *minus* the 5-year CMS rate on the relevant interest determination date, which will be the second business day preceding the respective interest period), subject to the maximum interest rate of 10.00% per annum.

For each quarterly interest period after the fourth interest period, the interest rate per annum for such interest period will be equal to:

- if (i) the CMS spread *times* (ii) 5.00 is *greater than* or *equal to* 10.00%, the maximum interest rate of 10.00% per annum;
- if (i) the CMS spread *times* (ii) 5.00 is *less than* 10.00% but *greater than* 0%, (i) the CMS spread *times* (ii) 5.00;
- if the CMS spread is *equal to* or *less than* 0%, 0%.

**After the first four interest periods, if on any interest determination date the 30-year CMS rate does not exceed the 5-year CMS rate, you will receive no interest on your notes for such interest period, even if the CMS spread on subsequent days is *greater than* the CMS spread on the first four interest periods, the interest rate per annum will be subject to a maximum interest rate of 10.00%.**

**Your investment in the notes involves certain risks, including, among other things, our credit risk. See page S-4.**

You should read the additional disclosure herein so that you may better understand the terms and risks of your investment.

***The estimated value of your notes at the time the terms of your notes were set on the trade date (as determined by Goldman, Sachs & Co. and taking into account our credit spreads) was equal to approximately \$897 per \$1,000 of face amount, or 89.7% of the original issue price. The value of your notes at any time will reflect many factors and cannot be predicted.***

**Original issue date:** June 26, 2014

**Original issue price:** 100.00% of the face amount

**Underwriting discount:** 4.30% of the face amount

**Net proceeds to issuer:** 95.70% of the face amount

In addition to offers and sales at the initial price to public, the underwriters and/or dealers may offer the notes from time to time in secondary market transactions at market prices prevailing at the time of sale, at prices related to market prices or at negotiated prices.

**Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or the accuracy or completeness of the information contained in this prospectus supplement.**

**<http://www.oblible.com>**

upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. The notes are not insured by the Federal Deposit Insurance Corporation or any other governmental agency, nor are they obligations

## **Goldman, Sachs & Co.**

---

Prospectus Supplement No. 2944 dated June 23, 2014.

---

[Table of Contents](#)

The issue price, underwriting discount and net proceeds listed on the cover page hereof relate to the notes we sell initially. notes after the date of this prospectus supplement, at issue prices and with underwriting discounts and net proceeds that differ. The return (whether positive or negative) on your investment in notes will depend in part on the issue price you pay for such notes.

Goldman Sachs may use this prospectus supplement in the initial sale of the offered notes. In addition, Goldman, Sachs & Goldman Sachs may use this prospectus supplement in a market-making transaction in a note after its initial sale. ***Unless Goldman Sachs otherwise indicates in the confirmation of sale, this prospectus supplement is being used in a market-making transaction.***

**About Your Prospectus**

The notes are part of the Medium-Term Notes, Series D program of The Goldman Sachs Group, Inc. The prospectus includes the accompanying documents listed below. This prospectus supplement constitutes a supplement to the documents listed below and may be used with such documents:

- [Prospectus supplement dated September 19, 2011](#)
- [Prospectus dated September 19, 2011](#)

The information in this prospectus supplement supersedes any conflicting information in the documents listed above. In addition, the information described in the listed documents may not apply to your notes.

[Table of Contents](#)**SUMMARY INFORMATION**

*We refer to the notes we are offering by this prospectus supplement as the “offered notes” or the “notes”. Each of the offered notes, has the terms described below and under “Specific Terms of Your Notes” on page S-10. Please note that in this prospectus supplement, “The Goldman Sachs Group, Inc.”, “we”, “our” and “us” mean only The Goldman Sachs Group, Inc. and do not include its subsidiaries. Also, references to the “accompanying prospectus” mean the accompanying prospectus, dated September 19, 2011 as supplemented by this prospectus supplement, dated September 19, 2011, relating to Medium-Term Notes, Series D, of The Goldman Sachs Group, Inc. The “indenture” in this prospectus supplement mean the senior debt indenture, dated July 16, 2008, between The Goldman Sachs Group, Inc. and New York Mellon, as trustee.*

**Key Terms**

**Issuer:** The Goldman Sachs Group, Inc.

**CMS spread:** on any interest determination date, the *difference* of the 30-year CMS rate *minus* the 5-year CMS rate.

**30-year CMS rate:** for any interest determination date, the 30-year U.S. dollar interest rate swap rate (as described on page S-11) on such day, subject to adjustment as described elsewhere in this prospectus supplement

**5-year CMS rate:** for any interest determination date, the 5-year U.S. dollar interest rate swap rate (as described on page S-11) on such day, subject to adjustment as described elsewhere in this prospectus supplement

**Face amount:** each note will have a face amount equal to \$1,000; \$2,000,000 in the aggregate for all the offered notes; the aggregate face amount of the offered notes may be increased if the issuer, at its sole option, decides to sell an additional amount of the offered notes on a date subsequent to the date of this prospectus supplement

**Supplemental discussion of U.S. federal income tax consequences:** We intend to treat the notes as debt instruments subject to the special rules governing contingent payment debt instruments for U.S. federal income tax purposes. Under this treatment, it is the opinion of Sidley Austin LLP that if you are a U.S. individual or taxable entity, you generally should be required to pay taxes on ordinary income from the notes over their term based on the comparable yield for the notes, subject to any positive and negative adjustments based on the actual interest payments on the notes. In addition, any gain you may recognize on the

sale, exchange, redemption or maturity of the notes, will be subject to U.S. federal income tax.

**Trade date:** June 23, 2014

**Original issue date (settlement date):** June 26, 2014

**Stated maturity date:** June 26, 2029, subject to adjustment as described under “Specific Terms of Your Notes” and to adjustment as described under “Specimen Payment of Principal on Stated Maturity Date” on page S-11

**Specified currency:** U.S. dollars (“\$”)

**Denominations:** \$1,000 or integral multiples thereof

**Interest payment dates:** March 26, June 26, September 26 and December 26 of each year, beginning on September 26, 2014 and ending on the stated maturity date, subject to adjustment as described elsewhere in the prospectus supplement

**Early redemption:** we have the right to redeem the notes, in part, at a price equal to 100% of the face amount of the notes plus interest, on each interest payment date on or after the stated maturity date, subject to five business days’ prior notice

**Interest rate:** for the first four interest periods, 9.00% per annum. For each interest period thereafter, the interest rate will be based on the

Prospectus Supplement No. 2944 dated June 23, 2014

<http://www.sec.gov/Archives/edgar/data/88>

relevant interest determination date for such  
per annum equal to:

S-2

---

**Table of Contents**

- if (i) the CMS spread *times* (ii) 5.00 is *greater than* or *equal to* the maximum interest rate: the maximum interest rate;
- if (i) the CMS spread *times* (ii) 5.00 is *less than* the maximum interest rate but *greater than* 0%: (i) the CMS spread *times* (ii) 5.00; or
- if the CMS spread is *equal to* or *less than* 0%: 0%

**Maximum interest rate:** 10.00% per annum

**Day count convention:** 30/360 (ISDA)

**Business day convention:** following unadjusted

**Regular record dates:** the scheduled business day immediately preceding each interest payment date

**Defeasance:** not applicable

**No listing:** the offered notes will not be listed or displayed on any securities exchange or interdealer market quotation system

**Business day:** as described on page S-13

**U.S. Government securities business day:** any day except for a Saturday, Sunday or a day on which the Securities Industry and Financial Markets Association recommends that the fixed income department of its members be closed for the entire day for purposes of trading in U.S. government securities

**Interest determination dates:** for each interest period, the second U.S. Government securities auction date preceding such interest period

**Interest period:** the period from and including the original issue date, in the case of the initial interest period, excluding the next succeeding interest payment date, in the case of the final interest period)

**FDIC:** The notes are not bank deposits and are not insured by the Federal Deposit Insurance Corporation (the "FDIC") or any other federal agency, nor are they obligations of, or guaranteed by, any federal agency

**Calculation agent:** Goldman, Sachs & Co.

**CUSIP no.:** 38147QA89

**ISIN no.:** US38147QA894

### ADDITIONAL RISK FACTORS SPECIFIC TO YOUR NOTES

**The Estimated Value of Your Notes At the Time the Terms of Your Notes Were Set On the Trade Date (as Determined By Reference to Pricing Models Used By Goldman, Sachs & Co.) Was Less Than the Original Issue Price Of Your Notes**

our models due to, among other things, any assumptions used by others. See “— The Model May Be Influenced by Many Factors That Act in Complex Ways” below.

In addition to the factors discussed above, your notes at any time will reflect many factors. Goldman, Sachs & Co. makes a market in the notes, and Goldman, Sachs & Co. would reflect any changes in the market, including any deterioration in the perceived creditworthiness. These changes may affect the price of your notes, including the price you may receive in a liquidating transaction. To the extent that Goldman, Sachs & Co. makes a market in the notes, the quoted price will reflect the market price determined by reference to Goldman, Sachs & Co. at the time, plus or minus its then current bid and ask price for structured notes.

## [Table of Contents](#)

Furthermore, if you sell your notes, you will likely be charged a commission for secondary market transactions, or the price will likely reflect a dealer discount. This commission or discount will further reduce the proceeds you would receive for your notes in a secondary market sale.

There is no assurance that Goldman, Sachs & Co. or any other party will be willing to purchase your notes at any price and, in this regard, Goldman, Sachs & Co. is not obligated to make a market in the notes. See “— Your Notes May Not Have an Active Trading Market” below.

### **The Notes Are Subject to the Credit Risk of the Issuer**

Although the return on the notes will be based in part on the relationship between the 5-year CMS rate and the 30-year CMS rate, the payment of any amount due on the notes is subject to our credit risk. The notes are our unsecured obligations. Investors are dependent on our ability to pay all amounts due on the notes, and therefore investors are subject to our credit risk and to changes in the market's view of our creditworthiness. See “Description of the Notes We May Offer — Information About Our Medium-Term Notes, Series D Program — How the Notes Rank Against Other Debt” on page S-4 of the accompanying prospectus supplement.

### **If the CMS Spread Changes, the Market Value of Your Notes May Not Change in the Same Manner**

The price of your notes may move differently than the CMS spread. The CMS spread will vary during the term of the notes based on the relationship between the 5-year CMS rate and the 30-year CMS rate as well as the market's expectation of this relationship in the future. Changes in the CMS spread may not result in a comparable change in the market value of your notes. Even if the CMS spread is greater than 0% during some portion of the life of the offered notes after the first four interest periods, the market value of your notes may not increase in the same manner. We discuss some of the reasons for this disparity under “— The Market Value of Your Notes May Be Influenced by Many Factors That Are Unpredictable and Interrelated in Complex Ways” below.

Because of the long-dated maturity of your notes, the performance of the CMS spread will have a significant impact on the value of your notes than if your notes had a shorter maturity. In particular, the expected future performance of the CMS spread and the market value of your notes to decrease or increase may be greater than 0% during some portion of the term of your notes. Moreover, expectations about the performance of the CMS spread in the future are subject to a great degree of uncertainty. Our assumptions about the future that may prove to be incorrect and the expected future performance of the CMS spread may result in market participants' expectations of future performance when determining the market value of your notes.

### **If the CMS Spread Is Less than or Equal to 0% on the Interest Determination Date for Any Interest Period, No Interest Will Be Paid**

Because of the formula used to calculate the interest payable on your notes, in the event that on the interest determination date for any interest period after the first four interest periods the 30-year CMS rate does not exceed the 5-year CMS rate, no interest will be paid for such interest period. If the 30-year CMS rate on subsequent days is *greater than* 0%, the interest payable on your notes on subsequent days is *greater than* 0%. The interest payable on your notes does not exceed the 5-year CMS rate for the entire term of your notes over the life of your notes after the first four interest periods, including interest determination dates, you will not receive interest on the affected interest periods. In such case, the interest payments on some or all of the interest periods may be reduced, and the overall return you earn on your notes may be less than the return earned by investing in a non-indexed debt security with the same maturity that bears interest at a prevailing market rate.

Assuming circumstances where no interest is paid on your notes after the fourth interest period, the interest payable on your notes of the original issue date will equal the present value of the coupons up to and including the fourth interest period, the maturity and face value of your notes.



## [Table of Contents](#)

amount issued by us, in each case discounted using current interest rates and credit spreads based on the discount method used by Goldman, Sachs & Co., which may be different from the methods used by others. On the original issue date such present value will be approximately 59.4203% of the face amount of your notes (you should not base any tax characterization of your notes on such present value).

### **The Amount of Interest Payable on Your Notes After the First Four Interest Periods Will Not Be Affected by the CMS Spread on Any Day Other Than the Interest Determination Date for the Applicable Interest Period**

For each interest period after the first four interest periods, the amount of interest payable on each interest payment date is calculated based on the CMS spread on the interest determination date for the applicable interest period. Although the actual CMS spread on an interest payment date or at other times after the first four interest periods may be higher than the CMS spread on the interest determination date, you will not benefit from the CMS spread at any time other than on such interest determination date.

### **The Amount of Interest Payable On The Notes In Any Quarter Is Capped**

For each of the first four interest periods, interest will be paid at a rate of 9.00% per annum (equal to a quarterly interest payment of \$22.50 for each \$1,000 face amount of notes). After the first four interest periods, the interest rate will be subject to the maximum interest rate of 10.00% per annum, which will limit the amount of interest you may receive on each interest payment date. Because of the formula used to calculate the interest rate on your notes, if (i) the CMS spread times (ii) 5.00 is greater than or equal to 10.00% per annum, the interest rate after the first four interest periods will be capped at 10.00% per annum (equal to a maximum quarterly interest payment of \$25.00 for each \$1,000 face amount of notes). Thus, you will not benefit from any increases in the CMS spread above 2.00%. Furthermore, since the interest rate is determined quarterly, if the interest rate for at least one interest period after the first four interest periods during any year is less than 10.00% per annum, your actual return

for such year will be less than 10.00% per annum. The CMS spread of 10.00% per annum for the remaining interest periods of the year. The notes may provide less interest income than other instruments.

### **The Historical Levels of the CMS Spread and Future Levels of the CMS Spread**

In the past, the level of the CMS spread has fluctuated. You should note that historical levels of the CMS spread are not necessarily indicative of future levels. An upward or downward trend in the CMS spread may indicate that the CMS spread is more or less likely to increase or decrease in the first four interest periods, and you should not use the CMS spread as an indication of its future levels.

### **Recent Regulatory Investigations Regarding ISDAfix May Adversely Affect the Value of Your Notes**

It has been reported that the U.K. Financial Conduct Authority and the U.S. Commodity Futures Trading Commission are investigating potential manipulation of ISDAfix. These investigations may have resulted in this rate or the quarterly interest rate being artificially lower (or higher) than it would otherwise be. Reforms affecting the determination or supervision of these investigations, may result in a sudden or significant decrease in reported ISDAfix or the quarterly interest rate. This could have an adverse impact on the trading value of securities such as your notes, the value of your notes.

### **If You Purchase Your Notes at a Premium, the Amount of Interest Payable on Your Investment Will Be Lower Than if You Purchase at Face Amount and the Impact of Certain Events May Be Negatively Affected**

The amount you will be paid for your notes will not be adjusted based on the issue price of your notes.

Prospectus Supplement No. 2944 dated June 23, 2014

<http://www.sec.gov/Archives/edgar/data/88>

S-6

[Table of Contents](#)

If you purchase notes at a price that differs from the face amount of the notes, then the return on your investment in such notes held to the stated maturity date or the date of early redemption will differ from, and may be substantially less than, the return on notes purchased at face amount. If you purchase your notes at a premium to face amount and hold them to the stated maturity date or the date of early redemption the return on your investment in the notes will be lower than it would have been had you purchased the notes at face amount or a discount to face amount.

**The Market Value of Your Notes May Be Influenced by Many Factors That Are Unpredictable and Interrelated in Complex Ways**

When we refer to the market value of your notes, we mean the value that you could receive for your notes if you chose to sell it in the open market before the stated maturity date. A number of factors, many of which are beyond our control, will influence the market value of your notes, including:

- the 30-year CMS rate and the 5-year CMS rate;
- the volatility — *i.e.*, the frequency and magnitude of changes — in the level of the CMS spread;
- economic, financial, regulatory, political, military and other events that affect CMS rates generally;
- interest rates and yield rates in the market;
- the time remaining until your notes mature; and
- our creditworthiness, whether actual or perceived, and including actual or anticipated upgrades or downgrades in our credit ratings or changes in other credit measures.

These factors, and many other factors, will influence the price you will receive if you sell your notes before maturity, including the price you may receive for your notes in any market making transaction. If you sell your notes before maturity, you may receive less than the face amount of your notes.

You cannot predict the future performance of the notes based on its historical performance. The actual performance of the notes over the life of the offered notes after the first four interest payments may differ from the interest payable on each interest payment due to the hypothetical levels of the CMS spread shown elsewhere in this prospectus supplement.

**Goldman Sachs' Anticipated Hedging Activities May Cause Changes in the Value of the Notes and Cause Our Clients and Counterparties to Be Contrained in Their Use of the Notes**

Goldman Sachs expects to hedge our obligations by purchasing futures and/or other instruments. We also expect to adjust our hedge by, among other things, entering into any of the foregoing, and perhaps other instruments, at any time and from time to time, and on or before the final interest payment on the notes. We may also enter into, adjust and unwind other transactions relating to other rate-linked notes whose returns are linked to the level of the CMS spread.

Any of these hedging or other activities may cause changes in the CMS spread and therefore the market value of the notes. The amount we will pay on your notes. In addition, our hedging transactions will cause Goldman Sachs or its affiliates to have economic interests and incentives that do not necessarily correspond directly contrary to, those of an investor in the notes. We have no obligation to take, refrain from taking or to disclose in respect to these transactions based on the price of the notes, and may receive substantial returns on our hedging while the value of your notes declines.

**As Calculation Agent, Goldman, Sachs & Co. May Make Determinations that Could Affect the Amount You May Receive On Any Note**

As calculation agent for your notes, Goldman Sachs & Co. has discretion in

Prospectus Supplement No. 2944 dated June 23, 2014

<http://www.sec.gov/Archives/edgar/data/88>

S-7

---

## [Table of Contents](#)

making certain determinations that affect your notes, including determining the CMS spread on any interest determination date in certain circumstances, which we will use to determine the amount, if any, we will pay on any applicable interest payment date after the first four interest payment dates. See “Specific Terms of Your Notes” below. The exercise of this discretion by Goldman, Sachs & Co. could adversely affect the value of your notes and may present Goldman, Sachs & Co. with a conflict of interest. We may change the calculation agent at any time without notice and Goldman, Sachs & Co. may resign as calculation agent at any time upon 60 days’ written notice to Goldman Sachs.

### **Your Notes May Not Have an Active Trading Market**

Your notes will not be listed or displayed on any securities exchange or included in any interdealer market quotation system, and there may be little or no secondary market for your notes. Even if a secondary market for your notes develops, it may not provide significant liquidity and we expect that transaction costs in any secondary market would be high. As a result, the difference between bid and asked prices for your notes in any secondary market could be substantial.

### **We Are Able to Redeem Your Notes at Our Option**

On any interest payment date on or after December 26, 2014, we will be permitted to redeem your notes at our option. Even if we do not exercise our option to redeem your notes, our ability to do so may adversely affect the value of your notes. It is our sole option whether to redeem your notes prior to maturity and we may or may not exercise this option for any reason. Because of this redemption option, the term of your notes could be anywhere between six months and fifteen years.

### **Certain Considerations for Insurance Companies and Employee Benefit Plans**

Any insurance company or fiduciary of a pension plan or other employee benefit plan that is subject to the prohibited transaction rules of the Employee Retirement Income Security Act of 1974, as amended, which we call “ERISA”, or the Internal Revenue Code of 1986, as amended, including an IRA or a Keogh plan (or

a governmental plan to which similar prohibitions apply), considering purchasing the offered notes with assets of such a plan, should consult with its counsel regarding whether the purchase or holding of the notes is a “prohibited transaction” under ERISA, the Internal Revenue Code, or a substantially similar prohibition in light of the facts and circumstances. A holder in any of the above categories is deemed to be holding the offered notes. This is discussed in “ERISA, the Retirement Income Security Act” below.

### **We May Sell an Additional Aggregate Face Amount of Notes at a Different Issue Price**

At our sole option, we may decide to sell an additional aggregate face amount of the notes subsequent to the date of this prospectus supplement. The issue price of the notes in the subsequent offering may be (higher or lower) from the issue price you paid for the notes in this prospectus supplement.

### **We Intend to Treat the Notes as Debt Instruments for Federal Income Tax Purposes**

We intend to treat the notes as debt instruments for federal income tax purposes. Under this treatment, if you are a U.S. person, you generally should be required to pay taxes on the interest on the notes over their term based on the comparable yield of the notes, including any positive and negative adjustments based on the notes. This comparable yield is determined by the amount on which you will be taxed prior to maturity. We make no guarantee of what the actual yield will be. We will recognize on the sale, exchange, redemption or maturity of the notes as ordinary interest income. If you are a U.S. person, the tax consequences to you may be different from those

Prospectus Supplement No. 2944 dated June 23, 2014

<http://www.sec.gov/Archives/edgar/data/88>

S-8

---

**[Table of Contents](#)**

It is possible that the Internal Revenue Service could successfully assert that your notes should be treated as variable rate debt instruments. If the notes are so treated you would include the full interest payment in ordinary income at the time you receive or accrue such interest payment, depending on your method of accounting for tax purposes. You should consult your tax advisor concerning possible further U.S. federal income tax ramifications if your notes are so treated.

Please see “Supplemental Discussion of Federal Income Tax Consequences” below for a more detailed discussion. Please also consult your own tax advisor concerning the U.S. federal income tax and any other applicable tax consequences to you of owning your notes in your particular circumstances.

[Table of Contents](#)

**SPECIFIC TERMS OF YOUR NOTES**

*We refer to the notes we are offering by this prospectus supplement as the “offered notes” or the “notes”. Please supplement, references to “The Goldman Sachs Group, Inc.”, “we”, “our” and “us” mean only The Goldman Sachs Group, consolidated subsidiaries. Also, references to the “accompanying prospectus” mean the accompanying prospectus, dated September 19, 2011, relating to Medium-Term Notes, Series D, supplemented by the accompanying prospectus supplement, dated September 19, 2011, relating to Medium-Term Notes, Series D, The Goldman Sachs Group, Inc. Please note that in this section entitled “Specific Terms of Your Notes”, references to “holders” mean those who own the notes in their own names, on the books that we or the trustee maintain for this purpose, and not those who own beneficial interests in the notes issued in book-entry form through The Depository Trust Company. Please review the special considerations that apply to the interests in the accompanying prospectus, under “Legal Ownership and Book-Entry Issuance”.*

The offered notes are part of a series of debt securities, entitled “Medium-Term Notes, Series D”, that we may issue under the indenture from time to time as described in the accompanying prospectus supplement and accompanying prospectus. The offered notes are also “indexed debt securities”, as defined in the accompanying prospectus.

This prospectus supplement summarizes specific financial and other terms that apply to the offered notes, including your notes; terms that apply generally to all Series D medium-term notes are described in “Description of Notes We May Offer” in the accompanying prospectus supplement. The terms described here supplement those described in the accompanying prospectus supplement and the accompanying prospectus and, if the terms described here are inconsistent with those described there, the terms described here are controlling.

In addition to those terms described on the first three pages of this prospectus supplement, the following terms will apply to your notes:

**Specified currency:**

- U.S. dollars (“\$”)

**Form of note:**

- global form only: yes, at DTC
- non-global form available: no

**Denominations:** each note registered in the name of a holder must have a face amount of \$1,000 or integral multiples of \$1,000 in excess thereof



**Defeasance applies as follows:**

- full defeasance: no
- covenant defeasance: no

**Other terms:**

- a business day for your notes will not be a business day for our other Series D medium-term notes. See "Special Calculation Provisions" below.

Please note that the information about the issue price, discount or commission and net proceeds for your notes on the front cover page or elsewhere in this prospectus supplement relates only to the initial issuance of your notes. We may decide to sell additional notes on or after the date of this prospectus supplement, at issue prices that result in net proceeds that differ from the amounts set forth in this prospectus supplement. If you purchase your notes in a market-making transaction after the initial issuance of your notes, any such relevant information about the net proceeds of a separate confirmation of sale.

We describe the terms of your notes in the following sections:

**Payment of Principal on Stated Maturity**

With respect to the offered notes that mature on the stated maturity date we will pay you an amount equal to the outstanding face amount of your notes.

[Table of Contents](#)**Stated Maturity Date**

The stated maturity date is June 26, 2029, subject to our early redemption right, unless that day is not a business day, in which case the stated maturity date will instead occur on the next succeeding business day.

**Interest Payments**

During the first four interest periods, the interest rate on the notes will be 9.00% per annum. For each interest period thereafter, the interest rate will be based upon the CMS spread on the relevant interest determination date for such interest period and will be a rate per annum equal to:

- if (i) the CMS spread *times* (ii) 5.00 is *greater than or equal to* the maximum interest rate, the maximum interest rate;
- if (i) the CMS spread *times* (ii) 5.00 is *less than* the maximum interest rate but *greater than* 0%, (i) the CMS spread *times* (ii) 5.00; or
- if the CMS spread is *equal to or less than* 0%, 0%.

The maximum interest rate is 10.00% per annum. Based on the formula used to calculate the interest rate on your notes, you will therefore not benefit from any increases in the CMS spread above 2.00%. Furthermore, if the CMS spread on the relevant interest determination date for any interest period after the first four interest periods is 0% or less, no interest will be paid for such interest period.

The calculation agent will calculate the amount of interest payable on each interest payment date for the applicable interest period after the first four interest periods in the following manner. For each \$1,000 face amount of your notes and for each interest period, the calculation agent will calculate the amount of interest to be paid by calculating the *product* of (i) the \$1,000 face amount *times* (ii) the interest rate *times* (iii) the applicable day count convention on a 30/360 basis.

Interest, if any, will be paid on your notes on the 26th day of each March, June, September and December, beginning on September 26, 2014 and ending on the stated

maturity date. If an interest payment date (or date that falls on the stated maturity date) falls on a business day, the payment due on such interest payment date shall be postponed to the next day that is a business day with respect to such interest payment date shall include such interest payment date to and including the day of such interest as so postponed. If the stated maturity date is not a business day, payment of principal and interest on such day will be made on the next succeeding business day. Interest on such payment shall accrue for the period from the stated maturity date.

**CMS Rate**

In this prospectus supplement, when we refer to the CMS rate, we mean the rate, on the applicable interest determination date, on the Reuters screen ISDAFIX1 page for 30-year CMS swaps, in the case may be, as of approximately 11:00 a.m. on the relevant interest determination date. If the CMS rate is not available in this manner, then:

- The applicable CMS rate for the relevant interest period will be determined on the basis of the CMS rate quotations provided by five leading market makers in the City interbank market at approximately 11:00 a.m. on any interest determination date. The CMS rate means the mean semi-annual swap rate means the mean CMS rate for the semi-annual fixed leg, calculated on the basis of a fixed-for-floating U.S. dollar interest rate swap term equal to thirty years or five years, as applicable, commencing on the relevant interest determination date, acknowledged dealer of good credit in the City, the floating leg, calculated on an Actual/360 day count convention to LIBOR with a designated maturity of 30 years or 5 years, may be determined in accordance with the “Description of Notes We May Offer – Floating Rate Notes” in the accompanying prospectus.

Prospectus Supplement No. 2944 dated June 23, 2014

<http://www.sec.gov/Archives/edgar/data/88>

S-11

agent will select the five swap dealers in its sole discretion and will request the principal New York City office of each of those dealers to provide a quotation of its rate.

- required to appoint a successor trustee. If the default or for any other reason, it may be difficult to find a qualified successor trustee. The trustee will remain in office under the indenture until a successor is appointed. During the period a successor is appointed, the trustee will have no authority under the indenture and (b) a conflicting interest under the purposes of the Trust Indenture Act. In the absence of a successor trustee as of September 19, 2011 under "Our Relationship with the Trust," there are certain other circumstances in which the trustee may have a conflict of interest.

## Manner of Paym

Any payment on your notes at maturity made to an account designated by the holder of the notes, or at the office of the trustee in New York, are surrendered to the trustee at that office. Interest payments will be made on the regular interest payment date by check mailed to the holder of the notes on the regular record date. We also may make any other payments in accordance with the applicable procedures of the depository.

## Modified Business

As described in the accompanying prospectus, we may issue medium-term notes that would otherwise be due on a day that is not a business day. Instead, they will be paid on the next day that is a business day, as if paid on the original due date. For your reference, a business day may have a different meaning than in the prospectus for the medium-term notes. We discuss this term under “Description of the Notes—Provisions” below.

### Role of Calculation

The calculation agent in its sole discretion regarding the CMS spread, the 30-year CMS interest determination dates, the regular record any, on each interest payment date, U.S. Government days, business days, postponement of the scheduled amount payable on your notes at

Prospectus Supplement No. 2944 dated June 23, 2014

<http://www.sec.gov/Archives/edgar/data/88>

S-12

## Table of Contents

maturity or redemption, as applicable. Absent manifest error, all determinations of the calculation agent will be final and binding on you and us, without any liability on the part of the calculation agent.

Please note that Goldman, Sachs & Co., our affiliate, is currently serving as the calculation agent as of the date of this prospectus supplement. We may change the calculation agent for your notes at any time after the date of this prospectus supplement without notice and Goldman, Sachs & Co. may resign as calculation agent at any time upon 60 days' written notice to Goldman Sachs.

### **Our Early Redemption Right**

We may redeem your notes, at our option, in whole but not in part, on any interest payment date on or after December 26, 2014, for an amount equal to 100% of the face amount *plus* any accrued and unpaid interest to, but excluding, the redemption date.

If we choose to exercise our early redemption right described in this prospectus supplement, we will notify the holder of your notes and the trustee by giving five business days' prior notice. The day we give the notice, which will be a business day, will be the redemption notice date and the immediately following interest payment date, which we will state in the redemption notice, will be the redemption date. We will not give a redemption notice that results in a redemption date later than the stated maturity date.

If we give the holder a redemption notice, we will redeem the entire outstanding face amount of your notes as follows. On the redemption date, we will pay to the holder of record on the business day immediately preceding the redemption date, the redemption price in cash, together with any accrued and unpaid interest to, but excluding, the redemption date, in the manner described under "Manner of Payment" above.

### **Special Calculation**

#### ***Business Day***

When we refer to a business day with respect to your notes, we mean any day that is a New York business day as defined in the "Business Days" section of the Debt Securities We May Offer — Payment Manner section on page 28 in the accompanying prospectus supplement.

#### ***U.S. Government securities business day***

When we refer to a U.S. Government securities business day with respect to your notes, we mean any day except a Saturday, Sunday, or U.S. Government securities market holiday on which the Securities Industry and Financial Markets Association (SIFMA) recommends that the fixed income department of the U.S. Government securities market be closed for the entire day for purposes of trading in U.S. Government securities.

---

[Table of Contents](#)

**USE OF PROCEEDS**

We will use the net proceeds we receive from the sale of the offered notes for the purposes we describe in the accompanying prospectus under “Use of Proceeds”.

**HEDGING**

In anticipation of the sale of the offered notes, we and/or our affiliates have entered into or expect to enter into hedging transactions involving purchases of instruments linked to CMS rates. In addition, from time to time, we and/or our affiliates expect to enter into additional hedging transactions and to unwind those we have entered into, in connection with the offered notes and perhaps in connection with other notes we issue, some of which may have returns linked to CMS rates. Consequently, with regard to your notes, from time to time, we and/or our affiliates:

- expect to acquire or dispose of positions in over-the-counter options, futures or other instruments linked to CMS rates, and/or
- may take short positions in securities of the kind described above — *i.e.*, we and/or our affiliates may sell securities of the kind that we do not own or that we borrow for delivery to purchaser.

We and/or our affiliates may also acquire securities similar to your notes from time to time at our discretion, hold or resell those securities.

In the future, we and/or our affiliates expect to enter into positions relating to the offered notes and perhaps other notes with returns linked to the CMS spread.

*The hedging activity discussed above may affect the value of your notes from time to time and at maturity. See “Additional Risk Factors” above for a discussion of these adverse effects.*

---

[Table of Contents](#)

## **HISTORICAL CMS SPREADS AND HYPOTHETICAL EXAMPLES**

### **Historical CMS Spreads**

The graph set forth below illustrates the historical CMS spreads from June 23, 2004 through June 23, 2014. We obtained the CMS spreads shown in the graph from Reuters, without independent verification.

The historical CMS spreads reflected in the graph set forth below are based on actual CMS rate movements during the time period. We cannot assure you, however, that this performance will be replicated in the future or that the historical CMS spreads will serve as a reliable indicator of future performance. The CMS spread has fluctuated in the past and may, in the future, experience significant fluctuations. Any historical upward or downward trend in the CMS spread during the period shown below is not an indication that the CMS spread is more or less likely to increase or decrease at any time after the first four interest periods. See “Additional Risk Factors Specific to Your Notes — Recent Regulatory Investigations Regarding Potential Manipulation of ISDAfix May Adversely Affect Your Notes” for more information relating

to the 30-year CMS rate and the 5-year CMS rate.

You should not take the historical CMS spreads as an indication of the future CMS spreads. We cannot assure you that the future CMS spreads will result in you receiving more interest payments *than* the interest payments you would have received if you invested in a non-indexed debt security of comparable maturity that bears interest at a prevailing market rate. We nor any of our affiliates make any representation about the CMS spread. In light of the increased volatility currently in the financial services sector and U.S. and global capital markets, market declines, it may be substantially more likely that interest payments less than the interest payments you would have received if you invested in a non-indexed debt security of comparable maturity that bears interest at a prevailing market rate.





S-15

## Hypothetical Examples

original issue price of your notes. For more information on the value of your notes, see “Additional Risk Factors—Your Notes May Be Worth Less Than the Original Issue Price” in this prospectus. The Estimated Value of Your Notes At the Time of the Redemption Were Set On the Trade Date (as Determined by the Pricing Agent Used By Goldman, Sachs & Co.) Was Less Than the Original Issue Price of Your Notes” on page S-4 of this prospectus.

For these reasons, the actual 30-year rate on any interest determination date for a four interest periods, as well as the interest date after the first four interest payment date hypothetical examples shown below. For information during recent periods, see “— Historical CMS Before investing in the notes, you should consult to determine the 30-year CMS rates and the date of this prospectus supplement and the notes.

The actual interest payment for any interest period will depend on the actual level of interest rates at the interest determination date. The applicable interest rate for each interest period will be determined quarterly on a per annum basis, based on the interest rate in effect at the end of the interest period. In addition, whether or not we will exercise our early redemption right at the end of each interest period will be determined at the hypothetical interest rate below would determine to exercise our early redemption right, which such interest rates would be applicable. These interest rates have been chosen arbitrarily for the purpose of this table and should not be taken as indicative of the future performance of the fund. The numbers appearing in the following table and the interest rates are for ease of analysis.

[Table of Contents](#)

Hypothetical 30-Year CMS Rate	Hypothetical 5- Year CMS Rate	30-Year CMS Rate Less 5- Year CMS Rate (the CMS Spread)	Hypothetical Interest Rate (Per Annum)
0.00%	8.00%	-8.00%	0.000%
3.00%	5.00%	-2.00%	0.000%
5.00%	5.00%	0.00%	0.000%
5.00%	4.50%	0.50%	2.500%
7.00%	6.00%	1.00%	5.000%
8.00%	5.50%	2.50%	10.000%
9.00%	3.00%	6.00%	10.000%
13.00%	2.00%	11.00%	10.000%

\*Assumes an interest period of 90 days

The following examples illustrate how the interest rates set forth in the table above are calculated.

**Example 1:** Based on a hypothetical 30-year CMS rate of 3.00% and a hypothetical 5-year CMS rate of 5.00%, the interest payable for the relevant interest payment date is calculated as follows:

**Step 1: Calculate the CMS spread**

The CMS spread is calculated as the *difference* between the hypothetical 30-year CMS rate of 3.00% and the hypothetical 5-year CMS rate of 5.00%:

$$\text{CMS spread} = -2.00\%$$

**Step 2: Calculate the interest rate (per annum)**

Because the CMS spread equals -2.00%, the interest rate for the relevant interest payment date shall be zero.

**Step 3: Calculate the quarterly interest payment for the relevant interest period**

interest period is zero because the CMS spread is 0.00%.

**Example 2:** Based on a hypothetical 30-year CMS rate of 7.00% and a hypothetical 5-year CMS rate of 6.00%, the interest payable for the relevant interest payment date is calculated as follows:

**Step 1: Calculate the CMS spread**

The CMS spread is calculated as the *difference* between the hypothetical 30-year CMS rate of 7.00% and the hypothetical 5-year CMS rate of 6.00%:

$$7.00\% - 6.00\% = 1.00\%$$

**Step 2: Calculate the interest rate (per annum)**

The per annum interest rate for the relevant interest period shall be the sum of (i) 1.00% *times* (ii) 5.00, subject to the maximum interest rate of 10.00% per annum, and shall be *no less than* zero. Given the CMS spread of 1.00%, which is *more than* zero and *less than* 10.00%, the relevant interest payment date shall be 5.00%.

The amount of interest payment for the relevant interest period equals the *product* of (i) the face amount *times* (ii) the interest rate *times* (iii) the applicable day count convention on a 30/360 basis. No adjustments will be made in the event an interest payment date is not a business day. The interest payment for this

***Step 3: Calculate the quarterly interest payment***

The amount of interest payment for the relevant interest period equals the *product* of (i) the face amount *times* (ii) the applicable day count convention on a

[Table of Contents](#)

30/360 basis. No adjustments will be made in the event an interest payment date is not a business day. The interest payment for this interest period with a hypothetical interest payment rate of 5.00% is \$12.50 for every \$1,000 face amount of notes, calculated as follows:

$$\$1,000 \times 5.00\% \times 90/360 = \$12.50$$

**Example 3:** Based on a hypothetical 30-year CMS rate of 9.00% and a hypothetical 5-year CMS rate of 3.00%, the interest payable for the relevant interest payment date is calculated as follows:

**Step 1: Calculate the CMS spread**

The CMS spread is calculated as the *difference* between the hypothetical 30-year CMS rate of 9.00% and the hypothetical 5-year CMS rate of 3.00%:

$$9.00\% - 3.00\% = 6.00\%$$

**Step 2: Calculate the interest rate (per annum)**

The per annum interest rate for the relevant interest period equals (i) 6.00% *times* (ii) 5.00, subject to the maximum interest rate of 10.00% per annum, and shall be *no less than* zero. Given that 6.00% *times* 5.00 equals 30.00%, which is *greater than* 10.00%, the interest rate for the relevant interest payment date shall be 10.00% (that is, shall be set equal to the maximum interest rate).

**Step 3: Calculate the quarterly interest payment for the relevant interest period**

The amount of interest payment for the relevant interest period equals the *product* of (i) the face amount *times* (ii) the interest rate *times* (iii) the applicable day count convention on a 30/360 basis. No adjustments will be made in the event an interest payment date is not a business day. The interest payment for this interest period with a hypothetical interest rate of 10.00% is \$25.00 for every \$1,000 face amount of notes, calculated as follows:

$$\$1,000 \times 10.00\% \times 90/360 = \$25.00$$

**Example 4:** Based on a hypothetical 30-year CMS rate of 13.00% and a hypothetical 5-year CMS rate of 2.00%, the interest payable for the relevant interest payment date is calculated as follows:

**Step 1: Calculate the CMS spread**

The CMS spread is calculated as the *difference* between the hypothetical 30-year CMS rate of 13.00% and the hypothetical 5-year CMS rate of 2.00%:

$$13.00\% - 2.00\% = 11.00\%$$

**Step 2: Calculate the interest rate (per annum)**

The per annum interest rate for the relevant interest period equals (i) 11.00% *times* (ii) 5.00, subject to the maximum interest rate of 10.00% per annum, and shall be *no less than* zero. Given that 11.00% *times* 5.00 equals 55.00%, which is *greater than* 10.00%, the interest rate for the relevant interest payment date shall be 10.00% (that is, shall be set equal to the maximum interest rate).

**Step 3: Calculate the quarterly interest payment for the relevant interest period**

The amount of interest payment for the relevant interest period equals the *product* of (i) the face amount *times* (ii) the interest rate *times* (iii) the applicable day count convention on a 30/360 basis. No adjustments will be made in the event an interest payment date is not a business day. The interest payment for this interest period with a hypothetical interest rate of 10.00% is \$25.00 for every \$1,000 face amount of notes, calculated as follows:

$$\$1,000 \times 10.00\% \times 90/360 = \$25.00$$

The payment amounts shown above are based on hypothetical interest rates that may differ from actual interest rates at the determination date and on assumptions that may differ from actual market value of your notes on the stated maturity date, including any time you may wish to sell your notes. The payment amounts should not be viewed as an indication of the actual interest payment amounts. Please read the prospectus for more information. Many Factors That are Unpredictable and Improbable are discussed on page S-7.

Prospectus Supplement No. 2944 dated June 23, 2014

<http://www.sec.gov/Archives/edgar/data/88>

S-18

---

[Table of Contents](#)

*We cannot predict the actual CMS spread on any interest determination date or the market value of your notes, n relationship between the CMS spread and the market value of your notes at any time prior to the stated maturity date and periods. The actual interest payment that a holder of the offered notes will receive at each interest payment date after the dates and the rate of return on the offered notes will depend on the actual CMS spread for each interest period after the t determined by the calculation agent over the life of your notes. Moreover, the assumptions on which the hypothetical exa be inaccurate. Consequently, the interest amount to be paid in respect of your notes, if any, on each interest payment da interest periods may be very different from the information reflected in the example above.*

[Table of Contents](#)**SUPPLEMENTAL DISCUSSION OF FEDERAL INCOME TAX CONSEQUENCES**

The following section supplements the discussion of U.S. federal income taxation in the accompanying prospectus.

The following section is the opinion of Sidley Austin LLP, counsel to The Goldman Sachs Group, Inc. It applies to you only if you hold your notes as a capital asset for tax purposes. This section does not apply to you if you are a member of a class of holders subject to special rules, such as:

- a dealer in securities or currencies;
- a trader in securities that elects to use a mark-to-market method of accounting for your securities holdings;
- a bank;
- a life insurance company;
- a tax-exempt organization;
- a partnership;
- a person that owns the notes as a hedge or that is hedged against interest rate risks;
- a person that owns the notes as part of a straddle or conversion transaction for tax purposes; or
- a United States holder whose functional currency for tax purposes is not the U.S. dollar.

This section is based on the U.S. Internal Revenue Code of 1986, as amended, its legislative history, existing and proposed regulations under the Internal Revenue Code, published rulings and court decisions, all as currently in effect. These laws are subject to change, possibly on a retroactive basis.

*You should consult your tax advisor concerning the U.S. federal income tax, and other tax consequences of your investment in the notes, including the application of state, local or other tax laws and the possible effects of changes in federal or other tax laws.*

**United States Holder**

This subsection describes the tax consequences for a United States holder. You are a United States holder if you are a United States resident and you are:

- a citizen or resident of the United States;
- a domestic corporation;
- an estate whose income is subject to U.S. federal income tax regardless of its source; or
- a trust if a United States court can exercise control over the trust's administration and one or more persons are authorized to control all substantial decisions of the trust.

If you are not a United States holder, the tax consequences for you will be described below under "Non-United States Aliens" and you should refer to "— United States Aliens" for more information.

**Tax Treatment.** The tax treatment of your notes will depend upon whether your notes are treated as variable rate debt instruments or as fixed rate instruments. We intend to treat your notes as variable rate instruments for U.S. federal income tax purposes. See below under "Alternative Treatments", the discussion of how your notes will be so treated.

Under the rules governing contingent payment debt instruments, the amount of interest you are required to take in each period will be determined by constructing a hypothetical non-contingent debt instrument and applying rules similar to those that apply to your notes and applying rules similar to those that apply to a discount on a hypothetical non-contingent debt instrument to the payment schedule. This method is applied by the IRS, which we would issue a non-contingent fixed rate debt instrument and conditions similar to your notes (the "contingent debt instrument") in determining as of the issue date a payment schedule that would produce a comparable yield. Under these rules, you will



Prospectus Supplement No. 2944 dated June 23, 2014

<http://www.sec.gov/Archives/edgar/data/88>

S-20

[Table of Contents](#)

interest based on the comparable yield. You will not have to separately include the amount of interest that you receive, except to the extent of any positive or negative adjustments discussed below.

It is not entirely clear how, under the rules governing contingent payment debt instruments, the maturity date for debt instruments (such as your notes) that provide for an early redemption right should be determined for purposes of computing the comparable yield and projected payment schedule. It would be reasonable, however, to compute the comparable yield and projected payment schedule for your notes (and we intend to make the computation in such a

manner) based on the assumption that your notes will mature on the stated maturity date.

We have determined that the comparable yield is 4.3758% per annum, compounded quarterly. If you are an initial holder that holds a note for a full year, your taxes on a calendar year basis, we have determined that you are required to report the following amounts as if you had received the interest into account any positive or negative adjustments to the interest into account based on the actual payments on the year:

Accrual Period	Interest Deemed to Accrue During Accrual Period (per \$1,000 note)
June 26, 2014 through December 31, 2014	\$22.22
January 1, 2015 through December 31, 2015	\$42.01
January 1, 2016 through December 31, 2016	\$40.84
January 1, 2017 through December 31, 2017	\$40.41
January 1, 2018 through December 31, 2018	\$40.29
January 1, 2019 through December 31, 2019	\$40.33
January 1, 2020 through December 31, 2020	\$40.46
January 1, 2021 through December 31, 2021	\$40.68
January 1, 2022 through December 31, 2022	\$40.97
January 1, 2023 through December 31, 2023	\$41.28
January 1, 2024 through December 31, 2024	\$41.65
January 1, 2025 through December 31, 2025	\$42.05
January 1, 2026 through December 31, 2026	\$42.44
January 1, 2027 through December 31, 2027	\$42.86
January 1, 2028 through December 31, 2028	\$43.28
January 1, 2029 through June 26, 2029	\$21.31

In addition, we have determined the projected payments for your notes are as follows:

Taxable Year:	Payment on March 26	Payment on June 26	Payment on September 26
2014	N/A	N/A	\$22.50
2015	\$22.50	\$22.50	\$17.66
2016	\$15.13	\$14.09	\$13.18
2017	\$11.88	\$11.42	\$11.02
2018	\$10.44	\$10.22	\$10.02

2019	\$9.70	\$9.56	\$9.43
2020	\$9.18	\$9.10	\$9.01
2021	\$8.80	\$8.72	\$8.60
2022	\$8.53	\$8.50	\$8.47
2023	\$8.42	\$8.37	\$8.35
2024	\$8.27	\$8.25	\$8.19
2025	\$8.18	\$8.19	\$8.20
2026	\$8.23	\$8.25	\$8.27
2027	\$8.31	\$8.30	\$8.33
2028	\$8.37	\$8.39	\$8.40
2029	\$8.42	\$1,008.43	N/A

S-21

## Table of Contents

*The comparable yield and projected payment schedule are not provided to you for any purpose other than the determination of your interest accruals in respect of your notes, and we make no representation regarding the amount of contingent payments with respect to your notes.*

If, during any taxable year, the actual payments with respect to the notes exceed the projected payments for that taxable year, you will incur a “net positive adjustment” under the contingent debt regulations equal to the amount of such excess. You will treat a net positive adjustment as additional interest income in that taxable year.

If, during any taxable year, the actual payments with respect to the notes are less than the amount of projected payments for that taxable year, you will incur a “net negative adjustment” under the contingent debt regulations equal to the amount of such deficit. This net negative adjustment will (a) reduce your interest income on the notes for that taxable year, and (b) to the extent of any excess after the application of (a), give rise to an ordinary loss to the extent of your interest income on the notes during prior taxable years, reduced to the extent such interest was offset by prior net negative adjustments. Any net negative adjustment in excess of the amounts described in (a) and (b) will be carried forward as a negative adjustment to offset future interest income with respect to the notes or to reduce the amount realized on a sale, exchange, redemption or maturity of the notes. A net negative adjustment is not subject to the two percent floor limitation on miscellaneous itemized deductions.

You are required to use the comparable yield and projected payment schedule that we compute in determining your interest accruals in respect of your notes, unless you timely disclose and justify on your U.S. federal income tax return the use of a different comparable yield and projected payment schedule.

Furthermore, it is possible that any Form 1099-OID you receive in respect of the notes may not take net negative or positive adjustments into account and therefore may overstate or understate your interest inclusions. You should consult your tax advisor as to

whether and how adjustments should be made on any Form 1099-OID.

If you purchase your notes at a price other than the adjusted issue price as determined for tax purposes, you must take into account the difference between the price you paid for your notes and the issue price is attributable to a change in expected interest payments, payment schedule, a change in interest rates, or other factors. We will allocate the difference accordingly. If the adjusted issue price is greater than the price you paid for your notes, we will make adjustments increasing (i) the amount of interest income each year, and (ii) the amount of ordinary income (or decreasing the amount of ordinary loss) recognized upon sale, exchange, redemption or maturity, by the amount of the difference between interest and projected payment schedule; if the adjusted issue price is less than the price you paid for your notes, we will make adjustments, decreasing (i) the amount of interest income each year, and (ii) the amount of ordinary income (or increasing the amount of ordinary loss) recognized upon sale, exchange, redemption or maturity by the amounts allocated to each of the years in the payment schedule. Adjustments allocated to the interest portion of the schedule date the daily portion of interest accrues.

The adjusted issue price of your notes is the original issue price plus any interest deemed to be a dividend under the rules governing contingent payment debt instruments. The adjusted issue price of your purchase your notes, decreased by the amount of any interest deemed to be a dividend, and the projected amount of any contingent payment in respect to the notes. The original issue price is the price at which a substantial amount of the notes were sold to bond houses, brokers, or similar persons or through the capacity of underwriters, placement agents,

Because any Form 1099-OID that you receive in respect of positive or negative adjustments resulting from the adjusted issue price other than the adjusted issue price determined

**Table of Contents**

purposes, you are urged to consult with your tax advisor as to whether and how adjustments should be made to the amounts reported on any Form 1099-OID.

You will recognize income or loss upon the sale, exchange, redemption or maturity of your notes in an amount equal to the difference, if any, between the amount of cash you receive at such time and your adjusted basis in your notes. In general, your adjusted basis in your notes will equal the amount you paid for your notes, increased by the amount of interest you previously accrued with respect to your notes (in accordance with the comparable yield for your notes), decreased by the amount of the fixed interest payments and the projected amount of any contingent payment previously made to you with respect to your notes and increased or decreased by the amount of any positive or negative adjustment, respectively, that you are required to make if you purchase your notes at a price other than the adjusted issue price determined for tax purposes.

Any income you recognize upon the sale, exchange, redemption or maturity of your notes will be ordinary interest income. Any loss you recognize at such time will be ordinary loss to the extent of interest you included as income in the current or previous taxable years in respect of your notes, and thereafter, capital loss. If you are a non-corporate holder, you would generally be able to use an ordinary loss to offset your income only in the taxable year in which you recognize the ordinary loss and would generally not be able to carry such ordinary loss forward or back to offset income in other taxable years.

**Alternative Treatments.** It is possible that the IRS could successfully assert that the notes should be treated as variable rate debt instruments for U.S. federal income tax purposes. If the notes are so treated, you will be subject to tax on interest payments, if any, as ordinary income at the time you receive or accrue such payments, depending on your method of accounting for tax purposes and any gain or loss you recognize upon the sale, exchange, redemption or maturity of your notes will be capital gain or loss. Please see the discussion under “United States Taxation — Taxation of Debt Securities — United States Holders — Variable Rate Debt Securities” in the accompanying prospectus for a detailed

description of the tax consequences of owning the instrument.

**United States Alien**

If you are a United States alien holder, “United States Taxation — Taxation of Debt Securities — United States Holders” in the accompanying prospectus for the notes describes the tax consequences relevant to you. You are a United States alien if you are the beneficial owner of the notes and are, for federal income tax purposes:

- a nonresident alien individual;
- a foreign corporation; or
- an estate or trust that in either case is not subject to federal income tax on a net income basis from the notes.

**Backup Withholding and Information Reporting**

Please see the discussion under “United States Taxation — Taxation of Debt Securities — Backup Withholding and Information Reporting” in the accompanying prospectus for a description of the backup withholding and information reporting rules that may apply to you.

**Foreign Account Tax Compliance Act (FATCA)**

Pursuant to Treasury regulations, Foreign Account Tax Compliance Act (FATCA) withholding (as described in “United States Taxation — Taxation of Debt Securities—Foreign Account Tax Compliance Act (FATCA)” in the accompanying prospectus) will generally not apply to obligations of the notes issued on or before July 1, 2014; therefore, the notes will not be subject to FATCA withholding.

---

**Table of Contents****EMPLOYEE RETIREMENT INCOME SECURITY ACT**

*This section is only relevant to you if you are an insurance company or the fiduciary of a pension plan or an employee benefit plan (including a governmental plan, an IRA or a Keogh Plan) proposing to invest in the notes.*

The U.S. Employee Retirement Income Security Act of 1974, as amended (“ERISA”) and the U.S. Internal Revenue Code of 1986, as amended (the “Code”), prohibit certain transactions (“prohibited transactions”) involving the assets of an employee benefit plan that is subject to the fiduciary responsibility provisions of ERISA or Section 4975 of the Code (including individual retirement accounts, Keogh plans and other plans described in Section 4975(e)(1) of the Code) (a “Plan”) and certain persons who are “parties in interest” (within the meaning of ERISA) or “disqualified persons” (within the meaning of the Code) with respect to the Plan; governmental plans may be subject to similar prohibitions unless an exemption applies to the transaction. The assets of a Plan may include assets held in the general account of an insurance company that are deemed “plan assets” under ERISA or assets of certain investment vehicles in which the Plan invests. Each of The Goldman Sachs Group, Inc. and certain of its affiliates may be considered a “party in interest” or a “disqualified person” with respect to many Plans, and, accordingly, prohibited transactions may arise if the notes are acquired by or on behalf of a Plan unless those notes are acquired and held pursuant to an available exemption. In general, available exemptions are: transactions effected on behalf of that Plan by a “qualified professional asset manager” (prohibited transaction exemption 84-14) or an “in-house asset manager” (prohibited transaction exemption 96-23), transactions involving insurance company general accounts (prohibited transaction exemption 95-60), transactions involving insurance company pooled separate accounts (prohibited

transaction exemption 90-1), transactions involving insurance company funds (prohibited transaction exemption 91-3), transactions with providers under Section 408(b)(17) of ERISA, and transactions with the Code where the Plan receives no less and no more than “adequate consideration” (within the meaning of Section 4975(f)(10) of the Code). The person or persons acting on behalf of a Plan or a governmental plan shall be deemed to have acted on behalf of the plan, by purchasing and holding the notes, or by disposing of the notes thereto, to represent that (a) the plan will receive no less than “adequate consideration” (within the meaning of Section 4975(f)(10) of the Code) for the purchase and holding of the notes, (b) none of the purposes for the purchase of the notes or the exercise of any rights related to the notes is a nonexempt prohibited transaction under ERISA, and (c) neither The Goldman Sachs Group, Inc. nor any of its affiliates is a “fiduciary” (within the meaning of Section 3(21) of ERISA) with respect to a governmental plan, under any similar application of ERISA with respect to the purchaser or holder in connection with the acquisition, disposition or holding of the notes. The Goldman Sachs Group, Inc. or any of its affiliates has no connection with the notes, and no advice provided by The Goldman Sachs Group, Inc. or any of its affiliates has formed the basis for any investment decision by or on behalf of such person or persons with the notes and the transactions contemplated

<p><i>If you are an insurance company or the fiduciary of a pension plan or an employee benefit plan (including a governmental plan), and propose to invest in the notes, you should consult your legal counsel.</i></p>
--

[Table of Contents](#)**SUPPLEMENTAL PLAN OF DISTRIBUTION**

The Goldman Sachs Group, Inc. has agreed to sell to Goldman, Sachs & Co., and Goldman, Sachs & Co. has agreed to purchase from The Goldman Sachs Group, Inc., the aggregate face amount of the offered notes specified on the front cover of this prospectus supplement. Goldman, Sachs & Co. proposes initially to offer the notes to the public at the original issue price set forth on the cover page of this prospectus supplement, and to certain securities dealers at such price less a concession not in excess of 3.75% of the face amount.

In the future, Goldman, Sachs & Co. or other affiliates of The Goldman Sachs Group, Inc. may repurchase and resell the offered notes in market-making transactions, with resales being made at prices related to prevailing market prices at the time of resale or at negotiated prices. The Goldman Sachs Group, Inc. estimates that its share of the total offering expenses, excluding underwriting discounts and commissions, will be approximately \$15,000. For more information about the plan of distribution and possible market-making activities, see "Plan of Distribution" in the accompanying prospectus.

We will deliver the notes against payment therefor in New York, New York on June 26, 2014, which is the third scheduled business day following the date of this prospectus supplement and of the pricing of the notes.

In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a "Relevant Member State") with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State (the "Relevant Implementation Date") an offer of the offered notes which are the subject of the offering contemplated by this prospectus supplement in relation thereto may not be made to the public in that Relevant Member State except that, with effect from and including the Relevant Implementation Date, an offer of such offered notes may be made to the public in that Relevant Member State:

(a) at any time to any legal entity which is a qualified investor as defined in the Prospectus Directive;

(b) at any time to fewer than 100 or, if the Issuer has not yet implemented the relevant provision of the 2003/71/EC (and amendments) Prospectus Directive, subject to obtaining the prior approval of the Dealer or Dealers nominated by the Issuer for the offer;

(c) at any time in any other circumstance permitted under the Prospectus Directive,

provided that no such offer of offered notes shall require the Issuer or any Dealer to publish a prospectus pursuant to Article 3 of the Prospectus Directive, or supplement the prospectus pursuant to Article 16 of the Prospectus Directive.

For the purposes of this provision, the expression "offer to the public" in relation to any notes in any Relevant Member State shall mean any communication in any form and by any means, whether or not it is an offer, in terms of the offer and the notes to be offered, which is directed to the public or which leads the public to decide to purchase or subscribe the notes, and which is made in a Relevant Member State by any measure implementing the Prospectus Directive in that Relevant Member State, the expression "offer" means Directive 2003/71/EC (and amendments) Prospectus Directive, to the extent implemented in that Relevant Member State, and includes any relevant implementing measure in that Relevant Member State and the expression "2010 PD Directive 2010/73/EU."

Goldman, Sachs & Co. has represented and warrants that:

(a) it has only communicated or caused to be communicated, or will only communicate or cause to be communicated, an offer of the offered notes to the public in the Relevant Member State in which it is engaged in investment activity (within the meaning of Article 1(2) of the Prospectus Directive) received by it in connection with the issue or the placing of the offered notes in the circumstances in which Section 21(1) of the Prospectus Directive applies to Goldman Sachs Group, Inc.; and

(b) it has complied and will comply with all applicable provisions of the FSMA with respect to the offer of the offered notes in the Relevant Member State in which it is engaged in investment activity (within the meaning of Article 1(2) of the Prospectus Directive) received by it in connection with the issue or the placing of the offered notes in the circumstances in which Section 21(1) of the Prospectus Directive applies to Goldman Sachs Group, Inc.;

Where the offered notes are subscribed by a relevant person (which is not an accredited investor (as defined in Section 275 of the SFA) whose sole business of which is to hold investments or which is owned by one or more individuals, each of whom is not an accredited investor; or (b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments or shares and debentures of that corporation or interest (howsoever described) in that trust six months after that corporation or that trust has been established pursuant to an offer made under Section 275 of the SFA) or by an institutional investor (for corporations, under Section 276(7) of the SFA), the transfer of the relevant securities to the relevant person defined in Section 275(2) of the SFA pursuant to an offer that is made on terms that require the units of shares and debentures of that corporation or interest in that trust to be acquired at a consideration of no less than the equivalent in a foreign currency) for each transfer of the relevant securities to be paid for in cash or by exchange of securities of the same class further for corporations, in accordance with the requirements of Section 275 of the SFA; (2) where no consideration is required for the transfer; (3) where the transfer is by operation of law; or (4) Section 276(7) of the SFA.



## VALIDITY OF THE NOTES

transfer or similar provision of applicable law above. This opinion is given as of the date hereof. The laws of the United States, the laws of the State of New York, the Corporation Law of the State of Delaware and the laws of the State of California, in addition, this opinion is subject to customary conditions, including the authorization, execution and delivery of the instrument, the signatures and certain factual matters, all as set forth in the opinion of counsel dated September 19, 2011, which has been filed with the SEC. The Goldman Sachs Group, Inc.'s registration statement is subject to review by the Securities and Exchange Commission.

[Table of Contents](#)

We have not authorized anyone to provide any information or to make any representations other than those contained or incorporated by reference in this prospectus supplement, the accompanying prospectus supplement or the accompanying prospectus. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus supplement, the accompanying prospectus supplement and the accompanying prospectus is an offer to sell only the notes offered hereby, but only under the circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus supplement, the accompanying prospectus supplement and the accompanying prospectus is current only as of the respective dates of such documents.

TABLE OF CONTENTS  
Prospectus Supplement

	Page
<a href="#">Summary Information</a>	S-2
<a href="#">Additional Risk Factors Specific to Your Notes</a>	S-4
<a href="#">Specific Terms of Your Notes</a>	S-10
<a href="#">Use of Proceeds</a>	S-14
<a href="#">Hedging</a>	S-14
<a href="#">Historical CMS Spreads and Hypothetical Examples</a>	S-15
<a href="#">Supplemental Discussion of Federal Income Tax Consequences</a>	S-20
<a href="#">Employee Retirement Income Security Act</a>	S-24
<a href="#">Supplemental Plan of Distribution</a>	S-25
<a href="#">Validity of the Notes</a>	S-27

Prospectus Supplement dated September 19, 2011

Use of Proceeds	S-2
Description of Notes We May Offer	S-3
United States Taxation	S-25
Employee Retirement Income Security Act	S-26
Supplemental Plan of Distribution	S-27
Validity of the Notes	S-28

Prospectus dated September 19, 2011

Available Information	2
Prospectus Summary	4
Use of Proceeds	8
Description of Debt Securities We May Offer	9
Description of Warrants We May Offer	33
Description of Purchase Contracts We May Offer	48
Description of Units We May Offer	53
Description of Preferred Stock We May Offer	58
The Issuer Trusts	65
Description of Capital Securities and Related Instruments	67
Description of Capital Stock of The Goldman Sachs Group, Inc.	88
Legal Ownership and Book-Entry Issuance	92
Considerations Relating to Floating Rate Debt Securities	97
Considerations Relating to Securities Issued in Bearer Form	98
Considerations Relating to Indexed Securities	102
Considerations Relating to Securities Denominated or Payable in or Linked to a Non-U.S. Dollar Currency	105

\$2,000,000

**The Goldman Sachs Group, Inc.**

Callable Quarterly CMS Spread-

**Goldman Sachs**

Considerations Relating to Capital Securities	108
United States Taxation	112
Plan of Distribution	135
Conflicts of Interest	137
Employee Retirement Income Security Act	138
Validity of the Securities	139
Experts	139
Review of Unaudited Condensed Consolidated Financial Statements by Independent Registered Public Accounting Firm	139
Cautionary Statement Pursuant to the Private Securities Litigation Reform Act of 1995	140

**Goldman, Sachs**